Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

The utility of hedgehog signaling pathway inhibition for cancer.

Sahebjam S, Siu LL, Razak AA.

Oncologist. 2012;17(8):1090-9. doi: 10.1634/theoncologist.2011-0450. Epub 2012 Jul 31. Review.

2.

Unraveling the therapeutic potential of the Hedgehog pathway in cancer.

Amakye D, Jagani Z, Dorsch M.

Nat Med. 2013 Nov;19(11):1410-22. doi: 10.1038/nm.3389. Epub 2013 Nov 7. Review.

PMID:
24202394
3.

Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.

You M, Varona-Santos J, Singh S, Robbins DJ, Savaraj N, Nguyen DM.

J Thorac Cardiovasc Surg. 2014 Jan;147(1):508-16. doi: 10.1016/j.jtcvs.2013.08.035. Epub 2013 Oct 4.

4.

CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance.

Yoon C, Park DJ, Schmidt B, Thomas NJ, Lee HJ, Kim TS, Janjigian YY, Cohen DJ, Yoon SS.

Clin Cancer Res. 2014 Aug 1;20(15):3974-88. doi: 10.1158/1078-0432.CCR-14-0011. Epub 2014 Jun 19.

5.

The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.

He M, Fu Y, Yan Y, Xiao Q, Wu H, Yao W, Zhao H, Zhao L, Jiang Q, Yu Z, Jin F, Mi X, Wang E, Cui Z, Fu L, Chen J, Wei M.

Clin Sci (Lond). 2015 Nov;129(9):809-22. doi: 10.1042/CS20140592. Epub 2015 Jul 2.

PMID:
26201092
6.

Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.

Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ.

Science. 2009 Oct 23;326(5952):572-4. doi: 10.1126/science.1179386. Epub 2009 Sep 2.

7.

Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells.

Justilien V, Fields AP.

Clin Cancer Res. 2015 Feb 1;21(3):505-13. doi: 10.1158/1078-0432.CCR-14-0507. Review.

8.

Molecular pathways: the hedgehog signaling pathway in cancer.

McMillan R, Matsui W.

Clin Cancer Res. 2012 Sep 15;18(18):4883-8. doi: 10.1158/1078-0432.CCR-11-2509. Epub 2012 Jun 19. Review.

9.

Hedgehog signaling pathway and cancer therapeutics: progress to date.

Ruch JM, Kim EJ.

Drugs. 2013 May;73(7):613-23. doi: 10.1007/s40265-013-0045-z. Review.

PMID:
23605693
10.

Hijacking the Hedgehog Pathway in Cancer Therapy.

Laukkanen MO, Castellone MD.

Anticancer Agents Med Chem. 2016;16(3):309-17. Review.

PMID:
26443025
11.

Nonclassical hedgehog-GLI signaling and its clinical implications.

Shevde LA, Samant RS.

Int J Cancer. 2014 Jul 1;135(1):1-6. doi: 10.1002/ijc.28424. Epub 2013 Sep 11. Review.

12.

Targeting Hedgehog signaling and understanding refractory response to treatment with Hedgehog pathway inhibitors.

Queiroz KC, Spek CA, Peppelenbosch MP.

Drug Resist Updat. 2012 Aug;15(4):211-22. doi: 10.1016/j.drup.2012.05.002. Epub 2012 Aug 19. Review.

PMID:
22910179
13.

Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.

Ramaswamy B, Lu Y, Teng KY, Nuovo G, Li X, Shapiro CL, Majumder S.

Cancer Res. 2012 Oct 1;72(19):5048-59. doi: 10.1158/0008-5472.CAN-12-1248. Epub 2012 Aug 8.

14.

Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL.

Decker S, Zirlik K, Djebatchie L, Hartmann D, Ihorst G, Schmitt-Graeff A, Herchenbach D, Jumaa H, Warmuth M, Veelken H, Dierks C.

Blood. 2012 Jan 26;119(4):997-1007. doi: 10.1182/blood-2011-06-359075. Epub 2011 Nov 30.

15.

Nonclassical activation of Hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to Smoothened-targeting Hedgehog inhibition.

Das S, Samant RS, Shevde LA.

J Biol Chem. 2013 Apr 26;288(17):11824-33. doi: 10.1074/jbc.M112.432302. Epub 2013 Mar 18.

16.

SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.

Della Corte CM, Bellevicine C, Vicidomini G, Vitagliano D, Malapelle U, Accardo M, Fabozzi A, Fiorelli A, Fasano M, Papaccio F, Martinelli E, Troiani T, Troncone G, Santini M, Bianco R, Ciardiello F, Morgillo F.

Clin Cancer Res. 2015 Oct 15;21(20):4686-97. doi: 10.1158/1078-0432.CCR-14-3319. Epub 2015 Jun 29.

17.

Inhibition of the hedgehog pathway targets the tumor-associated stroma in pancreatic cancer.

Hwang RF, Moore TT, Hattersley MM, Scarpitti M, Yang B, Devereaux E, Ramachandran V, Arumugam T, Ji B, Logsdon CD, Brown JL, Godin R.

Mol Cancer Res. 2012 Sep;10(9):1147-57. Epub 2012 Aug 2.

18.

MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.

Hoch L, Faure H, Roudaut H, Schoenfelder A, Mann A, Girard N, Bihannic L, Ayrault O, Petricci E, Taddei M, Rognan D, Ruat M.

FASEB J. 2015 May;29(5):1817-29. doi: 10.1096/fj.14-267849. Epub 2015 Jan 30.

19.

Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened.

Gonnissen A, Isebaert S, Haustermans K.

Oncotarget. 2015 Jun 10;6(16):13899-913. Review.

20.

Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.

Brechbiel J, Miller-Moslin K, Adjei AA.

Cancer Treat Rev. 2014 Jul;40(6):750-9. doi: 10.1016/j.ctrv.2014.02.003. Epub 2014 Feb 24. Review.

PMID:
24613036

Supplemental Content

Support Center